CTI BioPharma Corp.
CTIC · NASDAQ
3/31/2023 | 12/31/2022 | 9/30/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.21 | 0.00 | 0.30 | 0.17 |
| FCF Yield | -5.63% | -2.01% | -2.18% | -3.12% |
| EV / EBITDA | -73.57 | -57.74 | -64.43 | -34.87 |
| Quality | ||||
| ROIC | -16.27% | -14.21% | -12.98% | -18.04% |
| Gross Margin | 94.92% | 94.46% | 93.68% | 92.56% |
| Cash Conversion Ratio | 2.32 | 0.89 | 0.98 | 0.89 |
| Growth | ||||
| Revenue 3-Year CAGR | 4,231,427.67% | 3,778,449.50% | 3,203,054.44% | 85.56% |
| Free Cash Flow Growth | -100.50% | -0.30% | 23.62% | 32.47% |
| Safety | ||||
| Net Debt / EBITDA | -3.15 | -1.43 | -1.53 | 0.93 |
| Interest Coverage | -1.83 | -3.62 | -3.06 | -4.75 |
| Efficiency | ||||
| Inventory Turnover | 1.58 | 1.59 | 1.00 | 1.31 |
| Cash Conversion Cycle | -6.09 | -32.64 | -48.99 | -175.50 |